December 23 -- Beijing Double-Crane Pharmaceutical (600062.SH) plans to acquire Henan Shuanghe Huali Pharmaceutical for 110 million yuan in order to further up its market share of the transfusion products sector, reports yicai.com, citing a company filing.

The target company has a registered capital of 68 million yuan, and mainly produces large volume injections, granular formulations and hard capsules.

Huali Pharma had audited net assets of 68.04 million yuan, and an appraised value of 110 million yuan as of end October.

Source:CapitalVue